The AURELIA trial comparing the efficacy of bevacizumab plus chemotherapy, versus chemotherapy alone, presented encouraging results in platinum-resistant ovarian cancer patients.
An editorial published in the latest issue of the Journal of Clinical Oncology highlights the encouraging results reported by the AURELIA trial, a randomized trial comparing the effectiveness of chemotherapy (investigator’s choice of once-per-week paclitaxel, pegylated liposomal doxorubicin, or topotecan) combined with bevacizumab in recurrent platinum-resistant ovarian cancer. A companion article in the same issue reports patient-related outcomes (PROs) in AURELIA, evaluating abdominal/GI PROs in the patients.
Reflecting the results reported by previous trials that studied bevacizumab (GOG, ICON7 and OCEANS), AURELIA observed a statistically significant benefit in progression-free survival (PFS) by including bevacizumab in the chemotherapy regimen. A significant improvement (3.3 months) in median PFS was observed, with the patients in the bevacizumab plus chemotherapy arm presenting a median survival of 6.7 months (hazard ratio, 0.48; 95% confidence interval 0.38 to 0.60; P <0.001) compared to a median survival of 3.3 months observed in patients receiving chemotherapy alone. Further, similar to the OCEANS trial, overall response rate (OSS) significantly improved from 11.8% to 27.3% (P = 0.001) in the bevacizumab plus chemotherapy arm in the AURELIA trial, as assessed by the RECIST criteria.
Read the complete editorial here: http://bit.ly/1fevs2JSource: Journal of Clinical Oncology; Published online March 17, 2014
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Trastuzumab Deruxtecan Receives FDA Approval for HER2-Positive Solid Tumors
April 5th 2024FDA granted accelerated approval to trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive solid tumors who received prior systemic treatment and have no satisfactory alternative treatment options.
Read More